Viatris VTRS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Developed Markets Segment | $2.03B-10.3% | $2.26B-0.3% | $2.27B+6.4% | $2.13B+12.2% | $1.9B-11.9% | |
| Emerging Markets Segment | $537.4M-5.0% | $565.8M-1.0% | $571.8M+2.7% | $556.9M+6.5% | $523.1M+1.8% | |
| Greater China | $680.1M+18.7% | $572.9M-6.9% | $615.2M+4.5% | $588.9M+6.0% | $555.5M+6.4% | |
| Japan, Australia and New Zealand Segment | $273.5M-10.8% | $306.6M-0.2% | $307.3M+0.2% | $306.7M+10.7% | $277.1M-17.6% | |
| Operating Income (Loss) by Business | ||||||
| Developed Markets Segment | $780.8M— | —— | $944.1M+7.8% | $875.5M+18.6% | $738.1M— | |
| Emerging Markets Segment | $246.7M— | —— | $233.6M-1.9% | $238.1M+0.9% | $236M— | |
| Greater China | $497.3M— | —— | $416.8M+3.7% | $401.8M+4.4% | $384.7M— | |
| Japan, Australia and New Zealand Segment | $64.7M— | —— | $70.2M-16.1% | $83.7M+34.6% | $62.2M— | |
| Charges by Business | ||||||
| Corporate Segment and Other Operating Segment | $4.2M— | —— | —— | —— | —— | |
| Developed Markets Segment | $67.5M— | —— | —— | —— | —— | |
| Emerging Markets Segment | $5.7M— | —— | —— | —— | —— | |
| Greater China | $500K— | —— | —— | —— | —— | |
| Selling, general and administration by Business | ||||||
| Developed Markets Segment | $232.8M-8.7% | $255.1M+11.4% | $229M-8.2% | $249.5M+6.5% | $234.3M-14.4% | |
| Emerging Markets Segment | $71.1M-15.1% | $83.7M+13.7% | $73.6M-6.1% | $78.4M+5.5% | $74.3M+6.4% | |
| Greater China | $111.9M-22.6% | $144.6M+8.7% | $133M+6.7% | $124.6M+13.3% | $110M-19.5% | |
| Japan, Australia and New Zealand Segment | $34.4M-16.7% | $41.3M+9.0% | $37.9M-8.2% | $41.3M+7.6% | $38.4M-15.8% | |
| Cost of Sales by Business | ||||||
| Developed Markets Segment | $1.01B— | —— | $1.09B+8.7% | $1B+8.5% | $926.2M— | |
| Emerging Markets Segment | $219.6M— | —— | $264.6M+10.1% | $240.4M+13.0% | $212.8M— | |
| Greater China | $70.9M+14.5% | $61.9M-5.4% | $65.4M+4.6% | $62.5M+2.8% | $60.8M+1.3% | |
| Japan, Australia and New Zealand Segment | $174.4M— | —— | $199.2M+9.6% | $181.7M+2.9% | $176.5M— | |
| Foreign currency translation by Business | ||||||
| Developed Markets Segment | -$62.8M-417% | $19.8M— | $0-100% | $277M+10.7% | $250.3M+164% | |
| Emerging Markets Segment | -$1.7M— | —— | —— | $4.7M-39.7% | $7.8M+150% | |
| Greater China | $2.2M-47.6% | $4.2M+250% | $1.2M-73.3% | $4.5M+150% | $1.8M+117% | |
| Japan, Australia and New Zealand Segment | $0— | —— | —— | —— | $5.7M+146% | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | ||||||
| Developed Markets Segment | $3.19B0.0% | $3.19B0.0% | $3.19B0.0% | $3.19B0.0% | $3.19B+243% | |
| Emerging Markets Segment | $499M0.0% | $499M0.0% | $499M0.0% | $499M0.0% | $499M+502% | |
| Japan, Australia and New Zealand Segment | $651.8M0.0% | $651.8M0.0% | $651.8M0.0% | $651.8M0.0% | $651.8M+85.7% | |
| Goodwill by Business | ||||||
| Developed Markets Segment | $4.96B-1.2% | $5.02B+0.4% | $5B-0.3% | $5.02B+5.8% | $4.74B-29.8% | |
| Emerging Markets Segment | $795.3M-0.2% | $797M0.0% | $797.1M-0.5% | $801.3M+0.6% | $796.6M-31.6% | |
| Greater China | $935.4M+0.2% | $933.2M+0.5% | $929M+0.1% | $927.8M+0.5% | $923.3M+0.2% | |
| Japan, Australia and New Zealand Segment | $0— | $0— | $0— | $0— | $0-100% | |
| Net Sales by Product | ||||||
| Brands | $2.33B-0.6% | $2.35B-3.7% | $2.44B+6.7% | $2.28B+7.9% | $2.12B-2.3% | |
| Celebrex ® | $67.1M+1.4% | $66.2M-9.7% | $73.3M+4.7% | $70M+10.4% | $63.4M-5.5% | |
| Creon ® | $97.4M-1.5% | $98.9M+6.2% | $93.1M+1.9% | $91.4M+10.9% | $82.4M-8.8% | |
| Dymista ® | $37.3M-3.4% | $38.6M+14.2% | $33.8M-30.2% | $48.4M+13.1% | $42.8M+3.6% | |
| Effexor ® | $62M-9.0% | $68.1M+1.3% | $67.2M+6.5% | $63.1M+6.4% | $59.3M-8.1% | |
| EpiPen® Auto-Injectors | $101.1M+28.0% | $79M-49.7% | $157.2M+14.9% | $136.8M+41.5% | $96.7M+32.3% | |
| Generics | $1.18B-12.5% | $1.34B+2.6% | $1.31B+2.0% | $1.28B+14.0% | $1.13B-16.5% | |
| Lipitor | $462M+22.4% | $377.3M-4.7% | $396.1M+2.1% | $387.9M0.0% | $388M+9.0% | |
| Lyrica ® | $120.6M+0.7% | $119.8M-5.3% | $126.5M-1.2% | $128.1M+13.8% | $112.6M-11.3% | |
| Norvasc | $210M+19.9% | $175.2M-2.5% | $179.7M-1.6% | $182.7M+6.0% | $172.3M+3.7% | |
| Viagra ® | $95M-8.8% | $104.2M-1.0% | $105.2M+4.9% | $100.3M+1.8% | $98.5M+11.2% | |
| Xalabrands | $39.2M-6.7% | $42M+8.8% | $38.6M-5.2% | $40.7M+9.7% | $37.1M0.0% | |
| Xanax ® | $34.8M-11.9% | $39.5M+15.5% | $34.2M+0.9% | $33.9M+5.0% | $32.3M-11.5% | |
| Yupelri ® | $62.5M-11.5% | $70.6M-1.1% | $71.4M+7.2% | $66.6M+14.2% | $58.3M-12.5% | |
| Zoloft ® | $72.6M+8.7% | $66.8M0.0% | $66.8M+9.3% | $61.1M+1.5% | $60.2M+3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Viatris break its business down?
- Viatris (VTRS) reports net sales by business across 4 parts — Developed Markets Segment, Emerging Markets Segment, Greater China and Japan, Australia and New Zealand Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Viatris's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Viatris's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
